CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING 49% of Shares Voted, Quorum Not Established To Hold Annual Meeting Polls Remain Open Stockholders Holding Unvoted Proxies Are Strongly Encouraged to Vote Their

CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

of Shares Voted, Quorum Not Established To Hold Annual Meeting

Holding Unvoted Proxies Are Strongly Encouraged to Vote Their Shares

N.J., June 4, 2021 - Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy

and next-generation vaccines, announced that its 2021 Annual Meeting of Stockholders, originally scheduled for today, Friday, June 4,

2021 at 10:00 a.m., was adjourned and reconvened to 4:00 p.m. today, Friday, June 4, 2021, due to lack of the required quorum. Stockholders

will be able to attend the reconvened Annual Meeting virtually at www.virtualshareholdermeeting.com/CLSN2021.

is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including

immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2.

The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox ,

a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications.

Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA

or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For

more information on Celsion, visit www.celsion.com.

statements in this news release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform

Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation,

statements relating to the offering and the use of proceeds therefrom, unforeseen changes in the course of research and development activities

and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that

are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time and risk of failure of conducting

clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies,

assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from

time to time in the Celsion's periodic filings with the Securities and Exchange Commission. Celsion assumes no obligation to update

or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Vice President and CFO